School of Pharmacy, Qingdao University, Qingdao, China; The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China.
School of Pharmacy, Qingdao University, Qingdao, China.
Life Sci. 2019 Apr 15;223:174-184. doi: 10.1016/j.lfs.2019.03.032. Epub 2019 Mar 16.
Atherosclerosis (AS) is a chronic condition of the arterial vessels and a risk factor for myocardial infarction and stroke. Euxanthone is a xanthone compound extracted from Polygala caudata, and shows vasodilatory action. The aim of this study was to determine the potential pharmacological effects of euxanthone against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury.
Human umbilical vein endothelial cells (HUVECs) were exposed to ox-LDL, following pre-treatment with different concentrations of euxanthone. Viability, apoptosis and DNA fragmentation were respectively assessed by CCK-8 assay, Annexin-V/PI staining and TdT-mediated dUTP Nick-End Labeling (TUNEL) assay. The cellular levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were analyzed by enzyme linked immune-sorbent assays (ELISA), and reactive oxygen species (ROS) levels using dichlorodihydrofluorescin diacetate (DCFH) staining. Quantitative RT-PCR and Western blotting were respectively used to analyze the expression levels of specific mRNAs and proteins. HUVECs were transfected with Nrf2 siRNA to induce knockdown of the latter.
Euxanthone pre-treatment rescued the HUVECs from ox-LDL-induced cytotoxicity, apoptosis and DNA fragmentation in a dose-dependent manner. In addition, euxanthone also significantly reversed ox-LDL-triggered loss of mitochondrial membrane potential (MMP), cytochrome C release from mitochondria to cytosol, cleavage of caspase-3 and PARP, and increase in Bax/Bcl-2 ratio. Pre-treatment with euxanthone markedly suppressed ox-LDL-induced ROS generation and inhibition of antioxidant enzymes, as well as the up-regulation of pro-inflammatory factors like MCP-1, IL-1β and TNF-α in the HUVECs. Euxanthone up-regulated and activated Nrf2 by repressing Keap1, and increased the expression of its downstream genes HO-1 and NQO-1. Nrf2 knockdown abrogated the cyto-protective, anti-apoptotic, anti-oxidant and anti-inflammatory effects of euxanthone in ox-LDL-treated HUVECs. Finally, euxanthone activated Nrf2 via the MAPK pathway and blocking the latter likewise negated the protective effects of euxanthone against cell ox-LDL.
Euxanthone protected HUVECs against the oxidative and inflammatory damage induced by ox-LDL, indicating its potential as a novel therapeutic agent for AS.
动脉粥样硬化(AS)是一种动脉血管的慢性疾病,也是心肌梗死和中风的危险因素。山酮是从远志中提取的一种酮类化合物,具有血管扩张作用。本研究旨在探讨山酮对氧化型低密度脂蛋白(ox-LDL)诱导的内皮细胞损伤的潜在药理作用。
将人脐静脉内皮细胞(HUVECs)暴露于 ox-LDL 中,然后用不同浓度的山酮进行预处理。通过 CCK-8 法检测细胞活力,Annexin-V/PI 染色和 TdT 介导的 dUTP 缺口末端标记(TUNEL)法检测细胞凋亡和 DNA 片段化。通过酶联免疫吸附试验(ELISA)分析丙二醛(MDA)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和谷胱甘肽过氧化物酶(GSH-Px)的细胞水平,用二氯荧光素二乙酸酯(DCFH)染色法分析活性氧(ROS)水平。分别采用定量 RT-PCR 和 Western blot 分析特定 mRNA 和蛋白质的表达水平。用 Nrf2 siRNA 转染 HUVECs 以诱导后者敲低。
山酮预处理以剂量依赖的方式挽救了 ox-LDL 诱导的 HUVECs 细胞毒性、凋亡和 DNA 片段化。此外,山酮还显著逆转了 ox-LDL 触发的线粒体膜电位(MMP)丧失、细胞色素 C 从线粒体向细胞质释放、caspase-3 和 PARP 的切割以及 Bax/Bcl-2 比值的增加。山酮预处理显著抑制了 ox-LDL 诱导的 ROS 生成和抗氧化酶抑制,以及 MCP-1、IL-1β 和 TNF-α 等促炎因子在 HUVECs 中的上调。山酮通过抑制 Keap1 上调和激活 Nrf2,并增加其下游基因 HO-1 和 NQO-1 的表达。Nrf2 敲低消除了山酮在 ox-LDL 处理的 HUVECs 中的细胞保护、抗凋亡、抗氧化和抗炎作用。最后,山酮通过 MAPK 通路激活 Nrf2,阻断后者同样否定了山酮对细胞 ox-LDL 的保护作用。
山酮可保护 HUVECs 免受 ox-LDL 诱导的氧化和炎症损伤,表明其可能成为动脉粥样硬化的一种新型治疗药物。